Alpharma — Merger or Acquisition (August 2008)
7 slides from Alpharma's merger presentation, Aug 22, 2008
Slide 1: King Pharmaceuticals Proposed Acquisition of Alpharma Inc.
(c) King Pharmaceuticals, 2008. No materials contained in this presentation shall be reproduced or redistributed in any form. King Pharmaceuticals Proposed Acquisition of Alpharma Inc. August 22, 2008
Slide 2: Forward-looking Statements
Forward-looking Statements This document contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). King Pharmaceuticals, Inc. ("King") disclaims any intent or obligation to update these forward-looking statements, and claims the protection
Slide 3: Proposed Transaction
Proposed Transaction Price: $33 per share in cash 37% premium to Alpharma's closing price on August 21, 2008 49% premium to Alpharma's closing price on August 4, 2008 (the date of King's initial written offer) In excess of approximately 38% premium to Alpharma's average closing price for the one, th
Slide 4: Transaction Rationale: Creates Platform for Long-Term Growth
Transaction Rationale: Creates Platform for Long-Term Growth Creates a leading specialty pharmaceutical company with greater scale and capabilities Expanded portfolio of pain management products - including multiple platform technologies designed to deliver new innovative products Four potential pro
Slide 5: Combined Company Creates A Diversified Pain Portfolio
Combined Company Creates A Diversified Pain Portfolio Combined Skelaxin(r) Avinza(r) Remoxy(r) (NDA Filed) Acurox(tm) (Phase III) Kadian(r) Flector(r) Patch Embeda (NDA Submitted) Ketoprofen Gel (Phase III) T-62 (Phase II) EpiPen(r) Bio-defense products Vanquix (Phase III) King Skelaxin(r) Avinza(r)
Slide 6: Combined R&D Pipeline
Combined R&D Pipeline Product/Platform DESCRIPTION STATUS Remoxy(r) abuse-resistant Long-acting oxycodone capsules NDA Filed/Priority Review Embeda(tm) abuse-deterrent Long-acting morphine tablets NDA Submitted Acurox(tm) abuse-deterrent Short-acting oxycodone tablets NDA Submission 4Q/08 Ketoprofen
Slide 7: Compelling Combination
Compelling Combination Value creation for both King and Alpharma stockholders Strong strategic fit Opportunity to increase scale and depth in neuroscience/pain Excellent platform for sustainable, long-term growth King is committed to completing the Alpharma transaction